Saturday, March 19, 2016

Capital Square 1031 Acquires Medical Office Building in Winchester, VA

Louis Rogers
WINCHESTER, VA  – Capital Square 1031 announced the company has acquired a medical office building, 100 percent leased to Bio-Medical Applications of Virginia, doing business as Fresenius Medical Care Holdings Inc., in Winchester, Va.

Located at 38 W. Jubal Early Dr., the 9,503-square-foot, single-story condominium unit was recently built-to-suit for Fresenius, a wholly-owned subsidiary of Fresenius Medical Car AG & Co. KGaA.

“This is a recently-constructed, high quality medical office building on a long-term triple net lease to a subsidiary of the world’s leading provider of dialysis products and services. Its parent company had a net revenue of approximately $15.8 billion for the fiscal year 2014,” said Louis Rogers, founder and chief executive officer of Capital Square 1031.

According to Rogers, “Capital Square 1031 acquires medical properties throughout the nation because this desirable asset class is in great demand as a result of the ageing of the Baby Boomer generation.”

Listed on both the Frankfurt Stock Exchange (FME) and New York Stock Exchange (FMS), Fresenius is the world’s leading provider of products and services for people with chronic kidney failure.

 The company is primarily engaged in providing kidney dialysis services and clinical laboratory testing; manufacturing and distributing products and equipment for kidney dialysis treatment; and providing other medical ancillary services. 

During 2014, Fresenius cared for in excess of 283,000 dialysis patients in 3,349 proprietary clinics located in more than 45 countries worldwide. The company also operates more than 40 production sites on all continents, making Fresenius the leading provider of dialysis products, including dialysis machines, dialyzers and disposable accessories.

 For a complete copy of the company’s news release, please contact:

 Julie Leber                                                                         
 Spotlight Marketing Communications                    
 949.427.5172, ext. 703                   

No comments: